Business

3D bioprinting tech wins Australian Museum Eureka Prize 2021

On Friday, the Australian Museum Eureka Prize 2021 introduced that the RASTRUM printer developed by Inventia Life Science had received first place in its Eureka Prize for Innovative Use of Technology. Inventia’s 3D bio-printer RASTRUM makes use of inkjet printer know-how to print lifelike human cells. 

The revolutionary know-how will advance researchers’ means to grasp how new medication and coverings will react with actual residing cells. The know-how is presently getting used to print most cancers cells so researchers can take a look at and optimise chemotherapy and different most cancers remedies.

Inventia

Inventia Life Science is an Australian biotech startup firm situated in Sydney. Founded in 2013, its purpose is  “The growth, manufacture and sale of apparatus and reagents for superior medical analysis assays by way of 3D bioprinting,” with an emphasis on low-cost, standardised know-how to remodel medical analysis.

An organization consultant spoke in regards to the funding the corporate has acquired to carry its 3D bioprinting tech to life. 

“Inventia was initially funded by its founder, Dr Julio Ribeiro, from 2011 to 2017, when it acquired its Seed spherical of $1.6m in early 2017 led by Blackbird Ventures, and an oversubscribed Series A spherical of $10m in late 2018 that mixed lots of Australia’s main VC funds – Blackbird, Skip Capital, Main Sequence and AirTree.”

In the journey, Inventia Life Science acquired each federal & NSW authorities grants to carry the RASTRUM platform to market. 

“Through even handed use of this capital and authorities funding, Inventia was in a position to launch the RASTRUM platform and safe main international prospects – an unimaginable achievement contemplating the capital normally required to launch a platform of this nature.” 

What is Bio-Printing

Digital bioprinting is an extension of conventional 3D printing know-how that permits for the manufacturing of residing and non-living organic tissue reminiscent of residing cells or molecules. The printers work equally to 3D printers, however as an alternative of manufacturing layers of supplies reminiscent of plastic, they produce layers of biomaterial.  

Bioprinting know-how is shortly gaining traction and use amongst each universities and pharmaceutical corporations. The know-how rehearses the advantage of utilizing 3D cells quite than the historically used 2D cells. 

Inventia co-founder and CEO Dr Julio Ribeiro mentioned, “Culturing cells in 2D has been the bedrock of biomedical analysis and broadly used for over seven many years because of its simplicity. However, there’s a drawback with this strategy — cells within the physique don’t develop in 2D, however quite in a really complicated setting in 3-dimensions.” 

He continued: “3D cell cultures are due to this fact a significantly better mannequin for the in vivo setting and higher symbolize human tissue and the organic processes that impression mobile behaviour and drug responses. But as with all new know-how, there are challenges, particularly the lengthy time-consuming nature and excessive value of making ready 3D cell cultures by way of a course of that could be very guide and never scalable and reproducible.

“The 3D bioprinting area has expanded into many biomedical analysis purposes, reminiscent of regenerative drugs and drug discovery. 3D bioprinting strategies have enabled a major enhance within the effectivity of manufacturing of 3D cell cultures and likewise enabled their formation with excessive precision that will not be attainable manually.”

RASTRUM

RASTRUM is Inventia’s 3D bioprinting platform. It is the world’s first high-output 3D bioprinting platform. The vibrant pink 3D bioprinter’s compact dimensions make it excellent for benchtop laboratory use.

Dr Ribeiro mentioned, “The 3D cell cultures that RASTRUM produces are suitable with a various vary of workflows and evaluation strategies utilized in cell biology which signifies that the researcher can spend extra time on their analysis and fewer time on optimisation processes.” 

The RASTRUM platform represents a revolution within the area of biomedical analysis. The means to create 3D cell cultures that mimic human tissue has enormous analysis ramifications.

“Inventia Life Science have developed RASTRUM, which is the world’s first high-throughput 3D cell tradition platform that has been designed particularly for cell biology and is revolutionising biomedical analysis and drug growth.

“RASTRUM has been designed with simplicity in thoughts to make sure that anybody, even an individual with out prior expertise in bioprinting can use the platform and generate significant outcomes,” mentioned Dr Ribeiro. 

Other tech

Inventia is presently constructing upon its 3D bioprinting by creating know-how able to printing residing pores and skin. The know-how is hoped to remodel the remedy choices for broken pores and skin. By printing a brand new layer of pores and skin utilizing the affected person’s personal pores and skin cells, Inventia’s tech will pace up the restoration course of, cut back the probability of an infection, and cut back scarring. 

Dr Ribeiro mentioned, “Inventia is presently creating a pores and skin printing robotic named Ligō, which goals to remodel the best way clinicians strategy wound remedy and pores and skin regeneration. Inventia has partnered with world-renowned pores and skin surgeon Professor Fiona Wood (the University of Western Australia and Royal Perth Hospital) and main bioprinting researcher Professor Gordon Wallace (University of Wollongong), to handle the present challenges in pores and skin and wound remedy.

“The Ligō robotic prints stem cells and stem cell-like supplies in a managed method, and the printing course of is predicated on the identical drop-on-demand core know-how that’s discovered within the RASTRUM platform. In vivo research are presently ongoing with the aim of getting into first in human scientific trials throughout the subsequent two years.”

For extra info, please see inventiaskin.com

Read extra: Brisbane bio-tech agency lands $302 million U.S. contract for at-home COVID assessments

Read extra: Cancer analysis startup Inventia wins Australia’s high design prize

Keep updated with our tales on LinkedIn, Twitter, Facebook and Instagram.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button